Actively Recruiting
Extended Prone Positioning for Intubated ARDS
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-11-24
800
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute respiratory distress syndrome (ARDS) is an acutely induced respiratory failure characterised by the appearance of bilateral alveolar opacities on imaging and hypoxemia(1). Among strategies that have proved beneficial in terms of patient outcome, prone position (PP) is one associated with the greatest impact in terms of reduction in mortality, with PP sessions of 17h on average(2). The benefit of PP is to better homogenize the stress and strain applied to the lung by invasive ventilation. In a multicentric retrospective study involving COVID-19-related intubated ARDS patients, a strategy of extended PP, where PP was maintained for a median duration of 40 hours (h), was associated with increased survival compared to standard PP where each session lasted less than 24h(10). The main objective of this study is to investigate whether extended PP, defined as 40-hour PP sessions, can significantly reduce mortality of patients with invasively ventilated, severe ARDS, at day 28 after inclusion, compared to standard, 16-hour, PP sessions. The primary endpoint is all-cause mortality 28 days after inclusion. The study is a prospective, randomised, open-label, two-group parallel, multicenter trial comparing 40-hour extended PP to 16-hour standard PP in patients with moderate to severe ARDS. After inclusion, patients will be randomised either to standard PP, or extended PP. In the control arm, patients will be turned prone for 16-hour sessions. In the intervention arm, patients will be turned prone for 40h. In both groups, maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions to last 24 hours in the comparator group, and 48 hours in the intervention group. Inclusion criteria will be: severe ARDS, with ARDS defined according to the 2012 Berlin definition; and the severity defined as a PaO2/FiO2 ratio of \<150 mm Hg, with an FiO2 of ≥ 60% persisting for at least 4h after optimization of ventilatory setting. Exclusion criteria will be : PP during the same Intensive care unit ( ICU ) stay and before inclusion, ECMO before PP, arterio-venous ECMO, persistent PaO₂/FiO₂ ratios \<150 mm Hg, with FiO2 ≥ 60% on all arterial blood gases collected over a 24-hour period without prompting study inclusion, spine instability, intracranial pressure \> 20 mmHg, severe brain injury, hemodynamic instability deemed to contraindicate PP by the physician in charge.
CONDITIONS
Official Title
Extended Prone Positioning for Intubated ARDS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age of 18 years or older
- Admitted to ICU
- Under invasive ventilation for no more than 5 days
- Meet 2012 Berlin criteria for ARDS
- Protective ventilation at time of inclusion with plateau pressure below 35 cm H2O
- Tidal volume (VT) 8 ml/kg of predicted body weight or less
- Positive end-expiratory pressure (PEEP) of 5 cm H2O or higher
- Twice daily blood gases while FiO2 is 60% or higher before inclusion
- PaO2/FiO2 ratio of 150 mmHg or less with FiO2 60% or higher, and oxygen saturation between 92 and 96% after optimization of ventilator settings including PEEP set to 10 cm H2O and sedation or neuromuscular blockers if needed
You will not qualify if you...
- Prone positioning during the same ICU stay before inclusion
- Use of ECMO before prone positioning or arterio-venous ECMO
- Persistent PaO2/FiO2 ratio below 150 mmHg with FiO2 60% or higher on all blood gases over 24 hours without study inclusion
- Spine instability
- Intracranial pressure above 20 mmHg
- Severe brain injury
- Hemodynamic instability preventing prone positioning
- Home oxygen supplementation
- Care limited to comfort measures only
- Participation in another interventional study involving prone positioning with mortality as main outcome
- Already included in the PROSECO study
- Pregnancy
- Subject deprived of freedom or under conservatorship
- No insurance coverage
- Refusal to participate by patient or healthcare proxy or close relative
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Saint-Louis
Paris, France, 75010
Actively Recruiting
Research Team
T
Thaïs Walter, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here